Why Is Dermata Therapeutics Stock Up 200 percent Today?
DRMA Stock | USD 1.10 0.05 4.35% |
About 61% of Dermata Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Dermata Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Dermata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Dermata Therapeutics stock news signals to limit their universe of possible portfolio assets.
Dermata |
Dermata Therapeutics stock is up on Wednesday with heavy trading of the companys shares despite a lack of news this morning.
Read at investorplace.com
Dermata Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Dermata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Dermata Therapeutics Fundamental Analysis
We analyze Dermata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Dermata Therapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Dermata Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dermata Therapeutics stock to make a market-neutral strategy. Peer analysis of Dermata Therapeutics could also be used in its relative valuation, which is a method of valuing Dermata Therapeutics by comparing valuation metrics with similar companies.
Peers
Dermata Therapeutics Related Equities
IMMX | Immix Biopharma | 19.39 | ||||
WINT | Windtree Therapeutics | 8.89 | ||||
REVB | Revelation Biosciences | 0.67 | ||||
CDIO | Cardio Diagnostics | 0.33 | ||||
PHIO | Phio Pharmaceuticals | 0.00 | ||||
ZURA | Zura Bio | 0.33 | ||||
ATNF | 180 Life | 0.45 | ||||
ZVSA | ZyVersa Therapeutics | 3.60 | ||||
CYTO | Altamira Therapeutics | 4.17 | ||||
HEPA | Hepion Pharmaceuticals | 4.33 | ||||
SONN | Sonnet Biotherapeutics | 5.05 | ||||
ENSC | Ensysce Biosciences | 8.87 |
Complementary Tools for Dermata Stock analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |